Cameron Myhrvold, Carver Biosciences co-founder
September 15, 2022 09:50 AM EDT
Financing

The virus shred­der: A Prince­ton spin­out ad­vised by a high-pro­file VC launch­es a Cas13 vi­ral de­fense sys­tem

John Carroll

Editor & Founder

Cameron Myhrvold is one of those young sci­en­tists who’s been earn­ing dou­ble takes for the cut­ting-edge re­search work he’s been do­ing, even be­fore join­ing Prince­ton …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

A service from the Financial Times